Abstract
Use of adjuvant endocrine therapy for women with hormone-receptor (HR)-positive breast cancer has become the standard of care. Tamoxifen, an orally available selective estrogen receptor modulator (SERM), is a commonly used endocrine therapy agent currently recommended for use in pre- or post-menopausal women with HR-positive breast cancer. Current evidence suggests that prolonged tamoxifen use may be implicated in causing hepatotoxicity which may manifest as non-alcoholic steatohepatitis (NASH), cholestasis, cirrhosis, or hepatic necrosis. We herein present two cases of suspected tamoxifen-induced NASH resulting in fulminant liver failure. We also discuss literature surrounding tamoxifen-related hepatoxicity and implications in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
